Published in Dig Surg on April 01, 2010
Hormonal contraception--what kind, when, and for whom? Dtsch Arztebl Int (2011) 2.47
Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid. J Magn Reson Imaging (2012) 0.97
Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI. World J Hepatol (2014) 0.96
Hepatic pathology after Fontan palliation: spectrum of imaging findings. Pediatr Radiol (2012) 0.92
Liver masses: a clinical, radiologic, and pathologic perspective. Clin Gastroenterol Hepatol (2013) 0.81
Comparative histomorphological review of rat and human hepatocellular proliferative lesions. J Toxicol Pathol (2012) 0.80
MR Imaging of Hepatocellular Adenomas and Differential Diagnosis Dilemma. Int J Hepatol (2013) 0.79
Focal nodular hyperplasia: our experience of 53 Japanese cases. J Med Ultrason (2001) (2016) 0.78
Focal nodular hyperplasia: characterisation at gadoxetic acid-enhanced MRI and diffusion-weighted MRI. Br J Radiol (2013) 0.77
Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report. Childs Nerv Syst (2011) 0.76
Atypical Findings of Focal Nodular Hyperplasia with Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging. Iran J Radiol (2014) 0.75
Oestrogen hormone receptors in focal nodular hyperplasia. HPB (Oxford) (2015) 0.75
Von Meyenburg complexes mimicking metastatic disease at laparotomy for focal nodular hyperplasia. BMJ Case Rep (2013) 0.75
Hepatic focal nodular hyperplasia in children: imaging features on multi-slice computed tomography. World J Gastroenterol (2012) 0.75
A case of focal nodular hyperplasia with growth progression during pregnancy. Clin Mol Hepatol (2014) 0.75
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology (2012) 2.39
Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology (2010) 2.18
Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology (2013) 2.02
Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology (2002) 1.98
BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology (2004) 1.88
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol (2012) 1.84
High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol (2008) 1.72
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol (2012) 1.58
Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol (2011) 1.57
Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics (2004) 1.56
Pregnancy in primary sclerosing cholangitis. Gut (2011) 1.55
Primary biliary cirrhosis. Semin Immunopathol (2009) 1.46
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics (2007) 1.43
Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int (2014) 1.43
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology (2013) 1.39
Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol (2012) 1.29
Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis (2007) 1.27
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis (2012) 1.21
Overlap syndromes among autoimmune liver diseases. World J Gastroenterol (2008) 1.21
Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol (2012) 1.17
Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci (2006) 1.16
Bile salts and cholestasis. Dig Liver Dis (2010) 1.16
Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology (2005) 1.15
Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology (2014) 1.13
Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol (2002) 1.11
A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology (2012) 1.11
Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis (2004) 1.09
A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. Arch Toxicol (2014) 1.09
Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent. J Biol Chem (2008) 1.08
Antimitochondrial antibodies may be insufficiently specific to define primary biliary cirrhosis-like disease in mouse models. Hepatology (2013) 1.07
Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One (2010) 1.07
Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol (2006) 1.05
Testicular inflammation as a new manifestation of IgG4-associated disease. Urology (2013) 1.02
Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol (2012) 1.00
Mediators of pruritus during cholestasis. Curr Opin Gastroenterol (2011) 0.99
Immunoglobulin G4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion (2009) 0.97
Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol (2005) 0.95
Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. Eur Radiol (2013) 0.94
Pathogenesis and treatment of pruritus in cholestasis. Drugs (2008) 0.93
Intrahepatic cholestasis of pregnancy--a heterogeneous group of pregnancy-related disorders? Hepatology (2006) 0.92
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. Antivir Ther (2013) 0.92
IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol (2015) 0.91
Budesonide in previously untreated autoimmune hepatitis. Liver Int (2005) 0.91
Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. Biochem Biophys Res Commun (2007) 0.91
Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology (2014) 0.91
Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol (2006) 0.90
Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol Res (2002) 0.90
Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology (2003) 0.90
Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol (2011) 0.89
Comparison of interobserver agreement of magnetic resonance elastography with histopathological staging of liver fibrosis. Abdom Imaging (2014) 0.89
Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology (2004) 0.89
ABCB4 deficiency: A family saga of early onset cholelithiasis, sclerosing cholangitis and cirrhosis and a novel mutation in the ABCB4 gene. Hepatol Res (2010) 0.87
Predictors of premature delivery in patients with intrahepatic cholestasis of pregnancy. World J Gastroenterol (2007) 0.86
Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant (2007) 0.86
Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol (2008) 0.86
Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res (2007) 0.86
Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology (2006) 0.86
Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease. Scand J Gastroenterol (2008) 0.86
Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol (2006) 0.85
Phosphatidylinositol 3-kinase-dependent signaling modulates taurochenodeoxycholic acid-induced liver injury and cholestasis in perfused rat livers. Am J Physiol Gastrointest Liver Physiol (2005) 0.85
Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells. J Hepatol (2010) 0.85
Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. ASAIO J (2007) 0.85
Fucosyltransferase 2: a genetic risk factor for primary sclerosing cholangitis and Crohn's disease--a comprehensive review. Clin Rev Allergy Immunol (2015) 0.84
Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest (2006) 0.83
Polyinosinic acid blocks adeno-associated virus macrophage endocytosis in vitro and enhances adeno-associated virus liver-directed gene therapy in vivo. Hum Gene Ther (2013) 0.83
Effect of preoperative biliary drainage on coagulation and fibrinolysis in severe obstructive cholestasis. J Clin Gastroenterol (2010) 0.83
Liver failure in adult Still's disease during corticosteroid treatment. Eur J Gastroenterol Hepatol (2003) 0.82
Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis (2014) 0.82
The canalicular bile salt export pump BSEP (ABCB11) as a potential therapeutic target. Curr Drug Targets (2011) 0.82
Advances in pathogenesis and treatment of pruritus. Clin Liver Dis (2012) 0.82
Biomarkers for disease progression of primary sclerosing cholangitis. Curr Opin Gastroenterol (2015) 0.82
Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma. Inflamm Bowel Dis (2013) 0.82
Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology (2010) 0.82
Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol (2005) 0.82
Are pigs more human than mice? J Hepatol (2009) 0.81
The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology (2010) 0.81
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol (2017) 0.81
Tauroursodeoxycholic acid mobilizes alpha-PKC after uptake in human HepG2 hepatoma cells. Eur J Clin Invest (2002) 0.81
Cross-sectional imaging findings in congenital intestinal lymphangiectasia. J Comput Assist Tomogr (2002) 0.81
Decreased expression of breast cancer resistance protein in the duodenum in patients with obstructive cholestasis. Digestion (2006) 0.81
Diagnostic accuracy of (18) F-methylcholine positron emission tomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma. Hepatology (2014) 0.81
When bile acids don't get amidated. Gastroenterology (2013) 0.80
Targeting the ABCB4 gene to control cholesterol homeostasis. Expert Opin Ther Targets (2011) 0.80
The human transcription factor AP-1 is a mediator of bile acid-induced liver cell apoptosis. Biochem Biophys Res Commun (2005) 0.80
Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. Expert Rev Mol Diagn (2009) 0.80
Analysis of aberrant pre-messenger RNA splicing resulting from mutations in ATP8B1 and efficient in vitro rescue by adapted U1 small nuclear RNA. Hepatology (2015) 0.79
Extrahepatic manifestations of cholestasis. J Gastroenterol Hepatol (2002) 0.79
Serum Autotaxin Activity Correlates With Pruritus in Pediatric Cholestatic Disorders. J Pediatr Gastroenterol Nutr (2016) 0.79
Role of mitogen-activated protein kinases in tauroursodeoxycholic acid-induced bile formation in cholestatic rat liver. Hepatol Res (2008) 0.79
Is mipomersen ready for clinical implementation? A transatlantic dilemma. Curr Opin Lipidol (2013) 0.79
Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients. Eur J Gastroenterol Hepatol (2010) 0.79
Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol (2005) 0.79
Cytotoxic T lymphocyte antigen-4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis. Liver Int (2013) 0.79
Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Gastroenterol Hepatol (2014) 0.79
No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology (2005) 0.78
Biliary bicarbonate secretion constitutes a protective mechanism against bile acid-induced injury in man. Dig Dis (2011) 0.78
Predictors of posthepatectomy ascites with or without previous portal vein embolization. Dig Surg (2013) 0.78